Psoriasis--recent advances in understanding its pathogenesis and treatment.

Although not completely understood, there is clearly a genetic component in the development of psoriasis. Twin studies show a 67% concordance for monozygotic twins versus 18% for dizygotic twins. This lack of complete concordance in monozygotic twins suggests multifactorial inheritance and interaction between genetic predisposition and the environment. At present, 8 different psoriasis susceptibility loci have been identified in genome-wide linkage scans, including locations on 15 different chromosomes. Genetic connections have been made between psoriasis and other diseases, including atopic dermatitis, rheumatoid arthritis, and Crohn's disease. A variety of approaches are available for the treatment of psoriasis, ranging from topical agents for milder forms of the disease to phototherapy and systemic agents for severe psoriasis. Despite the importance of systemic therapies and recent advances represented by biologic agents, topical treatments will probably remain the mainstay of psoriasis therapy for most patients. The advent of new, cosmetically attractive vehicles may enhance compliance, add to the use of topical agents, and potentially improve patient outcomes.

[1]  D. Duffy,et al.  Psoriasis in Australian twins. , 1993, Journal of the American Academy of Dermatology.

[2]  C. Camisa,et al.  Handbook of Psoriasis , 1998 .

[3]  C. Griffiths,et al.  Natural killer and natural killer-T cells in psoriasis , 2002, Archives of Dermatological Research.

[4]  R. Trembath,et al.  Searching for the major histocompatibility complex psoriasis susceptibility gene. , 2002, The Journal of investigative dermatology.

[5]  H. Dvorak,et al.  Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis , 1994, The Journal of experimental medicine.

[6]  Gene regulation by steroid hormones , 1989, Cell.

[7]  M. Zanolli.  Phototherapy treatment of psoriasis today. , 2003, Journal of the American Academy of Dermatology.

[8]  V. Dixit,et al.  Keratinocytes as initiators of inflammation , 1991, The Lancet.

[9]  K. Gordon,et al.  The immunology of psoriasis and biologic immunotherapy. , 2003, Journal of the American Academy of Dermatology.

[10]  A. Bowcock,et al.  Genetics of psoriasis: the potential impact on new therapies. , 2003, Journal of the American Academy of Dermatology.

[11]  H. E. Hansen,et al.  Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. , 1982, Acta dermato-venereologica.

[12]  M. Detmar,et al.  Cytokine regulation of proliferation and ICAM-1 expression of human dermal microvascular endothelial cells in vitro. , 1992, The Journal of investigative dermatology.

[13]  W Sterry,et al.  IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. , 1998, The Journal of clinical investigation.

[14]  H. Tagami,et al.  Role of neutrophils in induction of acute inflammation in T‐cell‐mediated immune dermatosis, psoriasis: A neutrophil‐associated inflammation‐boosting loop , 2000, Experimental dermatology.

[15]  G. Weinstein,et al.  Cell kinetic basis for pathophysiology of psoriasis. , 1985, The Journal of investigative dermatology.

[16]  G. Abecasis,et al.  Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci , 2001, Nature Genetics.

[17]  M. Kawashima,et al.  An important role of tumor necrosis factor-α in the induction of adhesion molecules in psoriasis , 1998, Archives of Dermatological Research.

[18]  P. Guyre,et al.  Glucocorticoid effects on the production and actions of immune cytokines. , 1988, Journal of steroid biochemistry.

[19]  M. Diaz,et al.  Apoptosis in Proliferating, Senescent, and Immortalized Keratinocytes* , 1999, The Journal of Biological Chemistry.

[20]  G. Krueger,et al.  Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. , 2001, The New England journal of medicine.

[21]  G. Krueger,et al.  Development and use of alefacept to treat psoriasis. , 2003, Journal of the American Academy of Dermatology.

[22]  J. Yin,et al.  Psoriasis and bone marrow transplantation. , 1990, BMJ.

[23]  A. Gottlieb,et al.  Connections between psoriasis and Crohn's disease. , 2003, Journal of the American Academy of Dermatology.

[24]  X. Estivill,et al.  Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. , 2002, Human molecular genetics.

[25]  James T. Elder,et al.  Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? , 2000, Journal of the American Academy of Dermatology.

[26]  J. Krueger,et al.  PUVA‐induced lymphocyte apoptosis: Mechanism of action in psoriasis , 1999, Photodermatology, photoimmunology & photomedicine.

[27]  C I Amos,et al.  A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. , 2001, American journal of human genetics.

[28]  J. Snowden,et al.  Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity , 1997, The British journal of dermatology.

[29]  A. Gottlieb,et al.  Therapy of Moderate-to-Severe-Psoriasis, Second Edition , 2003 .

[30]  J. Ortonne,et al.  Pathophysiology of Psoriasis: Science behind Therapy , 2002 .

[31]  I. Leigh,et al.  Altered keratinocyte growth and differentiation in psoriasis. , 1995, Clinics in dermatology.

[32]  K. Gordon,et al.  Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis , 2004, Dermatologic therapy.

[33]  G. Gyapay,et al.  New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Gottlieb.  Infliximab for psoriasis. , 2003, Journal of the American Academy of Dermatology.

[35]  A. Cooper,et al.  The endothelium in psoriasis , 1995, The British journal of dermatology.

[36]  James T. Elder,et al.  Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. , 1997, Human molecular genetics.

[37]  A. Chang,et al.  Interleukin 2 and psoriasis. , 1988, Archives of dermatology.

[38]  R. Matre,et al.  Characterization of mononuclear cell infiltrates in psoriatic lesions. , 1978, The Journal of investigative dermatology.

[39]  N. Ifrah,et al.  Psoriasis after allogeneic bone marrow transplantation. , 1990, Archives of dermatology.

[40]  C. Leonardi.  Efalizumab: an overview. , 2003, Journal of the American Academy of Dermatology.

[41]  J. Cather,et al.  Etanercept: An overview. , 2003, Journal of the American Academy of Dermatology.

[42]  Stefan Jenisch,et al.  The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. , 2003, American journal of human genetics.

[43]  T. Annesley,et al.  Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. , 1991, The New England journal of medicine.

[44]  S. Feldman,et al.  Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. , 2003, Journal of the American Academy of Dermatology.

[45]  A. Gottlieb,et al.  TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. , 2002, Journal of drugs in dermatology : JDD.

[46]  K. Asadullah,et al.  Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. , 2001, The Journal of investigative dermatology.